Search Result

Pathways Recommended:	NF-κB MAPK/ERK Pathway Neuronal Signaling JAK/STAT Signaling

Results for "

TNF-α/NF-κB/MAPK signaling pathway

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NF-κB (25) p38 MAPK (23) TNF Receptor (16) 5-HT Receptor (1) Acyltransferase (2) Akt (3) Amyloid-β (1) Angiotensin Receptor (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (8) Autophagy (1) Bcl-2 Family (1) Beclin1 (1) Cannabinoid Receptor (1) Caspase (3) Cholinesterase (ChE) (3) COX (7) ERK (8) FAK (1) FXR (1) GLUT (1) Glycosidase (1) IKK (1) Integrin (1) Interleukin Related (13) IRAK (1) JNK (6) Keap1-Nrf2 (3) MAP3K (1) MDM-2/p53 (1) Mitochondrial Metabolism (1) MMP (1) mTOR (1) MyD88 (1) Necroptosis (1) NO Synthase (7) Parasite (1) Phosphatase (1) PI3K (1) Prostaglandin Receptor (3) Reactive Oxygen Species (ROS) (2) Reference Standards (2) SOD (1) STAT (1) Tau Protein (1) TGF-β Receptor (1) Toll-like Receptor (TLR) (4)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (26) Metabolic Disease (1) Neurological Disease (9)

By Targets:

NF-κB (25)

p38 MAPK (23)

TNF Receptor (16)

5-HT Receptor (1)

Acyltransferase (2)

Akt (3)

Amyloid-β (1)

Angiotensin Receptor (1)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (1)

Apoptosis (8)

Autophagy (1)

Bcl-2 Family (1)

Beclin1 (1)

Cannabinoid Receptor (1)

Caspase (3)

Cholinesterase (ChE) (3)

COX (7)

ERK (8)

FAK (1)

FXR (1)

GLUT (1)

Glycosidase (1)

IKK (1)

Integrin (1)

Interleukin Related (13)

IRAK (1)

JNK (6)

Keap1-Nrf2 (3)

MAP3K (1)

MDM-2/p53 (1)

Mitochondrial Metabolism (1)

MMP (1)

mTOR (1)

MyD88 (1)

Necroptosis (1)

NO Synthase (7)

Parasite (1)

Phosphatase (1)

PI3K (1)

Prostaglandin Receptor (3)

Reactive Oxygen Species (ROS) (2)

Reference Standards (2)

SOD (1)

STAT (1)

Tau Protein (1)

TGF-β Receptor (1)

Toll-like Receptor (TLR) (4)

By Research Areas:

Cancer (8)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (26)

Metabolic Disease (1)

Neurological Disease (9)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: NF-κB Tissue Factor Pathway Inhibitor (TFPI) RGS Protein TNF Receptor p38 MAPK MAP4K MAPKAPK2 (MK2) MNK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-123942

Diprovocim Maximum Cited Publications 14 Publications Verification	Toll-like Receptor (TLR) TNF Receptor p38 MAPK NF-κB	Inflammation/Immunology Cancer
Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC₅₀=110 pM). Diprovocim stimulates the release of *TNF-α* from mouse macrophages (EC₅₀=1.3 nM). Diprovocim activates downstream *MAPK* and *NF-κB* signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses .

HY-N6246

Asperulosidic Acid	NF-κB ERK	Inflammation/Immunology Cancer
Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the *NF-κB* and mitogen-activated protein kinase (MAPK) signaling pathways .

HY-120149

Inotodiol	Toll-like Receptor (TLR) MDM-2/p53 MMP Caspase SOD p38 MAPK NF-κB Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Inotodiol activates p53 signaling pathway, inhibits MMP-2/9, and exhibits antitumor activity in cancer cell HeLa. Inotodiol inhibits the generation of ROS and exhibits antioxidant and neuroprotective effects. Inotodiol inhibits the activation of *MAPK* and *NF-κB* signaling pathway, and exhibits anti-inflammatory activity. Inotodiol inhibits TLR-4 mediated TNF-α production (IC₅₀s in BMMC and BMDM is 0.7 μM and 3.0 μM), inhibits the degranulation in mast cell, exhibits anti-allergic activity. Inotodiol is orally active .

HY-N0631

Cornuside 5+ Cited Publications	p38 MAPK NF-κB JNK Cholinesterase (ChE) Acyltransferase NO Synthase Interleukin Related TNF Receptor Prostaglandin Receptor ERK COX	Neurological Disease Inflammation/Immunology
Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and *NF-κB* signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, *TNF-α, IL-6, and IL-1β*, by suppressing NF-κB activation .

HY-19667A

BMS-561392 formate 2 Publications Verification DPC 333 formate	TNF Receptor NF-κB Apoptosis p38 MAPK	Neurological Disease Inflammation/Immunology
BMS-561392 formate (DPC 333 formate) is a selective ADAM17(TACE) inhibitor. BMS-561392 formate inhibits *TNF-α* secretion by regulating signaling pathways such as p44 MAPK and *NF-κB. BMS-561392 formate also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 formate promotes microglial apoptosis*, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 formate can be used in research related to spinal cord injury and inflammatory diseases .

HY-P991400

GSK1995057	TNF Receptor Apoptosis Interleukin Related NF-κB JNK p38 MAPK	Inflammation/Immunology
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of *TNF-α* and LT-α, and does not interfere with TNFR2 signaling. GSK1995057 inhibits the activation of *NF-κB, JNK* and *MAPK* pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, *TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1* and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .

HY-19667

BMS-561392 DPC 333	TNF Receptor NF-κB Apoptosis p38 MAPK	Neurological Disease Inflammation/Immunology
BMS-561392 (BMS-561392) is a selective ADAM17(TACE) inhibitor. BMS-561392 inhibits *TNF-α* secretion by regulating signaling pathways such as p44 MAPK and *NF-κB. BMS-561392 also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 promotes microglial apoptosis*, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 can be used in research related to spinal cord injury and inflammatory diseases .

HY-118828B

12-Oxo phytodienoic acid (≥90%) 1 Publications Verification 12-OPDA (≥90%)	NF-κB p38 MAPK TNF Receptor Interleukin Related NO Synthase Keap1-Nrf2	Neurological Disease Inflammation/Immunology
12-Oxo phytodienoic acid (≥90%) (12-OPDA (≥90%)) is a plant lipid-derived anti-inflammatory compound. 12-Oxo phytodienoic acid (≥90%) induces the expression of SOCS-1 and inhibits LPS (HY-D1056)-induced activation of the *NF-κB* and p38 MAPK signaling pathways. 12-Oxo phytodienoic acid (≥90%) inhibits LPS-induced expression of IL-6 and *TNF-α, and reduces LPS-induced NO production by decreasing iNOS* levels. 12-Oxo phytodienoic acid (≥90%) induces activation of the Nrf2 signaling cascade. 12-Oxo phytodienoic acid (≥90%) can be used for the research of neurodegenerative diseases .

HY-121811

Pongamol Lanceolatin C	Glycosidase Phosphatase Interleukin Related TNF Receptor COX Beclin1 GLUT FAK Akt mTOR p38 MAPK Keap1-Nrf2 Apoptosis Amyloid-β Tau Protein Autophagy	Neurological Disease Inflammation/Immunology Cancer
Pongamol (Lanceolatin C) is an orally active flavonoid with an IC₅₀ of 75 μM and a K_i of 58 μM against PTPase-1B, and an IC₅₀ of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, *TNF‑α, COX‑2* and iNOS in cells, reverses the nuclear translocation of *NF‑κB, and upregulates the levels of Beclin 1* and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the *MAPKs/Nrf2* signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol exhibits antibacterial activity. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .

HY-176192

SMU-14a	Toll-like Receptor (TLR) NF-κB p38 MAPK ERK IKK TNF Receptor Interleukin Related	Inflammation/Immunology
SMU-14a is a selective Toll-like receptor 3 (TLR3) inhibitor wirh an IC₅₀ of 0.18 μM. SMU-14a reduces phosphorylation of p65, ERK, and TBK1 via *NF-κB, MAPK, and IRF3* signaling pathways. SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages, downregulates *TNF-α* in human peripheral blood monocytes and decreases serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used for the research of acute hepatitis .

HY-W342283

Diminazene	Parasite Angiotensin-converting Enzyme (ACE) Angiotensin Receptor p38 MAPK STAT NF-κB TNF Receptor 5-HT Receptor	Cardiovascular Disease Infection Inflammation/Immunology
Diminazene is an antiparasitic agent widely used to treat parasitic diseases caused by hemoparasites (such as trypanosomes and babesia). Diminazene acts as an ACE2 activator and exerts cardiovascular protective effects by activating the ACE2/Ang-(1-7)/Mas receptor axis. By regulating gut microbiota-tryptophan metabolism, Diminazene inhibits the activation of core inflammatory signaling pathways including *MAPK, STAT* and *NF-κB, increases central 5-HT* levels, and suppresses splenic *TNF-α* production, thereby alleviating systemic inflammation .

HY-N0887

Isoastragaloside I 2 Publications Verification Isoastragaloside-I	Akt NF-κB p38 MAPK PI3K FXR Keap1-Nrf2 NO Synthase COX Interleukin Related Integrin TGF-β Receptor Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Inflammation/Immunology
Isoastragaloside I is a natural compound found in Astragalus membranaceus, with oral activity and multiple biological activities such as anti-inflammatory and antioxidant properties. Isoastragaloside I inhibits Akt, *NF-κB, MAPKs* and PI3K, enhances the activity of hepatic FXR, regulates the TGF-β/Smads signaling pathway, and upregulates antioxidant molecules downstream of Nrf2. Isoastragaloside I inhibits the expression of NO, *TNF-α, iNOS, COX-2, IL-1β* and VCAM-1, and reduces intracellular ROS levels. Isoastragaloside I attenuates blood-brain barrier disruption, restores intestinal barrier function, increases β-cell mass, improves glucose homeostasis, and elevates circulating adiponectin levels. Isoastragaloside I can be used for the study of neuroinflammation-related neurodegenerative diseases, cholestatic liver disease, and diabetes .

HY-119420

Acetoxycycloheximide	Antibiotic Apoptosis Caspase JNK p38 MAPK TNF Receptor ERK NF-κB Mitochondrial Metabolism	Inflammation/Immunology Cancer
Acetoxycycloheximide is an antibiotic with antitumor activity. Acetoxycycloheximide a protein synthesis inhibitor. Acetoxycycloheximide significantly induces activation of procaspase-3 and subsequent apoptosis mediated by the Cytochrome c from mitochondria via activation of JNK pathway. Acetoxycycloheximide triggers the downregulation of cell surface TNF-R1 via the activation of ERK and p38 MAPK, thereby preventing activation of the *NF-κB* signaling pathway by TNF-α. Acetoxycycloheximide is much more toxic to female rats than to males. Acetoxycycloheximide can be used for inflammatory and immune diseases and cancers research .

HY-155753

Anti-inflammatory agent 50	NF-κB COX	Inflammation/Immunology
Anti-inflammatory agent 50 (compound a1) is a Fusidic acid derivative with anti-inflammatory effects. Anti-inflammatory agent 50 inhibits inflammatory factor NO, IL-6 and TNF-α. Anti-inflammatory agent 50 alleviates acute lung injury by regulating inflammatory mediators and suppressing the MAPK, NF-κB and NLRP3 inflammasome signaling pathways .

HY-173416

Anti-inflammatory agent 100	NF-κB p38 MAPK ERK JNK	Inflammation/Immunology
Anti-inflammatory agent 100 (Compound (+)-4S-23) is an anti-inflammatory agent. Anti-inflammatory agent 100 inhibits *MAPK* and *NF-κB* signaling, and also inhibits NF-κB pathway by suppressing the phosphorylation of IκB-α and blocking nuclear translocation of phosphorylated p65. Anti-inflammatory agent 100 inhibits NO production (IC₅₀: 0.5 μM) and TNF-α, IL-6, IL-1β secretion .

HY-157809

Anti-inflammatory agent 74	Interleukin Related TNF Receptor NF-κB p38 MAPK	Inflammation/Immunology
Anti-inflammatory agent 74 (B5) is an anti-inflammatory agent that can inhibit NO, IL-6, and *TNF-α, with IC₅₀* values of 10.88 μM and 4.93 μM for NO and IL-6, respectively. Anti-inflammatory agent 74 alleviates acute lung injury (ALI) by regulating inflammatory mediators and inhibiting the *MAPK* and *NF-κB* signaling pathways .

HY-N6246R

Asperulosidic Acid (Standard)	Reference Standards NF-κB ERK	Inflammation/Immunology Cancer
Asperulosidic Acid (Standard) is the analytical standard of Asperulosidic Acid. This product is intended for research and analytical applications. Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways .

HY-N15347

Talaromyketide B	NF-κB p38 MAPK Interleukin Related TNF Receptor NO Synthase COX	Inflammation/Immunology
Talaromyketide B is a polyketide compound with anti-inflammatory activity, discovered in the soil bacterium Talaromyces sp. KYS-41. Talaromyketide B inhibits the activation of the *NF-κB* and *MAPK* signaling pathways and dose-dependently suppresses pro-inflammatory cytokines, such as IL-1β, IL-6, IL-10, and *TNF-α, as well as the transcriptional activity of inflammatory mediators, including iNOS* and COX-2. Talaromyketide B holds potential for research in the fields of immunity and inflammatory diseases .

HY-172409

CB1R antagonist 2	Cannabinoid Receptor p38 MAPK NF-κB	Inflammation/Immunology
CB1R antagonist 2 (Compound 11g) is the antagonist for cannabinoid receptor 1 (CB1R), that inhibits *MAPK/NF-κB* signaling pathway and exhibits anti-inflammatory activity. CB1R antagonist 2 inhibits LPS (HY-D1056)-induced IL-6, IL-1β and TNF-α expressions in RAW264.7. CB1R antagonist 2 ameliorates OVA-induced allergic rhinitis in mouse models .

HY-N0631R

Cornuside (Standard)	Reference Standards Prostaglandin Receptor ERK p38 MAPK Acyltransferase TNF Receptor COX Cholinesterase (ChE) Interleukin Related JNK NO Synthase NF-κB	Neurological Disease Inflammation/Immunology
Cornuside (Standard) is the analytical standard of Cornuside (HY-N0631). This product is intended for research and analytical applications. Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and *NF-κB* signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, *TNF-α, IL-6, and IL-1β*, by suppressing NF-κB activation.

HY-172871

Anti-inflammatory agent 102	MAP3K p38 MAPK NF-κB Reactive Oxygen Species (ROS) NO Synthase Interleukin Related	Inflammation/Immunology
Anti-inflammatory agent 102 (Compound 11a) is an orally active anti-inflammatory agent. Anti-inflammatory agent 102 exerts its anti-inflammatory effect by blocking the activation of the ASK1/p38 MAPKs/NF-κB signaling pathway. Anti-inflammatory agent 102 has significant anti-inflammatory activity and can inhibit the release of NO, ROS, and inflammatory factors (such as IL-6, TNF-α, IL-1β). Anti-inflammatory agent 102 can be used in the study of inflammatory diseases such as ulcerative colitis (UC) .

HY-162641

AF-45	IRAK NF-κB p38 MAPK TNF Receptor	Inflammation/Immunology
AF-45 inhibits IRAK4 and IRAK1, with IC₅₀s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and *TNF-α* in macrophages, with IC₅₀s of 0.53-1.54 μM and 0.6-2.75 μM. AF-45 is also an inhibitor for *NF-κB/MAPK* signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models .

HY-N18025

Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside	NF-κB p38 MAPK Akt Prostaglandin Receptor TNF Receptor Interleukin Related NO Synthase COX	Inflammation/Immunology
Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside is an anti-inflammatory agent. Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside exerts significant anti-inflammatory effects in LPS (HY-D1056)-induced RAW 264.7 macrophages by inhibiting the *NF-κB, MAPK* and Akt signaling pathways, thereby reducing the production of inflammatory mediators (NO, PGE2) and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) .

HY-181073

Apoptosis/necroptosis inducer 1	Apoptosis Necroptosis NF-κB p38 MAPK	Neurological Disease Cancer
Apoptosis/necroptosis inducer 1 is an orally active and brain-penetrant apoptosis and necroptosis inducer. Apoptosis/necroptosis inducer 1 induces mitochondria-dependent (intrinsic pathway) apoptosis. Apoptosis/necroptosis inducer 1 induces necroptosis by activating the *TNF-α/NF-κB/MAPK* signaling pathway. Apoptosis/necroptosis inducer 1 exhibits antiproliferative activity in glioblastoma cell lines and multiple solid tumor types. Apoptosis/necroptosis inducer 1 inhibits growth of orthotopic glioblastoma in animal models and improves survival rate. Apoptosis/necroptosis inducer 1 can be used for the research of glioblastoma .

HY-107272

Chuanbeinone 22-Epidelavinone	Cholinesterase (ChE) Apoptosis Bcl-2 Family Caspase Interleukin Related TNF Receptor Toll-like Receptor (TLR) MyD88 NF-κB p38 MAPK	Inflammation/Immunology Cancer
Chuanbeinone (22-Epidelavinone) is an orally active alkaloid found in Fritillaria pallidiflora. Chuanbeinone shows cytotoxicity against mutiple cancer cells and can induces apoptosis and S phase arrest. Chuanbeinone downregulates Bcl-2, upregulates Bax, and activates caspase-3. Chuanbeinone exerts anti-inflammatory and antitussive effects by reducing pro-inflammatory cytokine (IL-1β, IL-6 and *TNF-α) production and mRNA expression, and inhibiting TRIF-, MyD88-, NF-κB-, and MAPK*-dependent signaling pathways. Chuanbeinone inhibits AChE and BChE with IC₅₀ values of 7.7 and 0.7 μM. Chuanbeinone can be used for the researches of lung carcinoma, cough, inflammatory diseases .

HY-P11617

CLP-d2	NF-κB ERK JNK p38 MAPK Interleukin Related	Inflammation/Immunology
CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor and immunomodulator with superior pharmacokinetic properties to Daptomycin (HY-B0108) and good safety profiles. CLP-d2 inhibits the *NF-κB* and *MAPK* signaling pathways by reducing the expression levels of c-Fos and NFATc1, and decreasing the phosphorylation levels of IκBα, p65, ERK and JNK, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, *TNF-α* and IL-1β to exert anti-inflammatory activity. CLP-d2 inhibits intra-articular osteoclastogenesis in mice, alleviates bone erosion and joint swelling, reduces synovial hyperplasia and inflammatory cell infiltration, and decreases serum rheumatoid factor (RF) levels. CLP-d2 is applicable to related research on rheumatoid arthritis .

HY-N9541

Chaetoglobosin Vb	Others	Inflammation/Immunology
Chaetoglobosin Vb is a novel cytotoxic alkaloid with anti-inflammatory and antioxidant activities. Chaetoglobosin Vb can inhibit oxidative stress induced by LPS stimulation, reduce the production of reactive oxygen species and increase the expression of the antioxidant enzyme superoxide dismutase (SOD). Chaetoglobosin Vb significantly reduced the gene and protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) induced by LPS, and alleviated the production of proinflammatory cytokines such as TNF-α, IL-6 and IL-1β. Chaetoglobosin Vb exerts its biological activity through the TLR4-mediated MyD88-dependent signaling pathway and the TRIF-dependent signaling pathway, which is specifically manifested by inhibiting the phosphorylation of p38, ERK, and JNK MAPK and the translocation of NF-κB p65 subunit to the nucleus. Chaetoglobosin Vb showed no cytotoxic effect in the concentration range of 25-100 μM and promoted SOD enzyme activity and phosphorylation of p38, ERK1/2 and JNK in a dose-dependent manner .

Cat. No.	Product Name	Target	Research Area